Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Dr. Jean-Pierre Bizzari

<< Previous

Bullboard Posts

Next >>

Comment by Azzak34on Dec 14, 2023 5:39pm

152 Views

Post# 35785626

RE:RE:RE:RE:RE:RE:RE:RE:RE:Dr. Jean-Pierre Bizzari

All you do is whine and compain.

So you got in too early, you hung on and hung on and the company made mistakes? Again, sounds like a you problem. You've made an investment that you're not happy with? That's.a.you.problem!!!

And don't pretend you're some sort of benevolent force for the poor downtrodden shareholders, you'd trample over everyone here for a few extra percent on the Share price. So when you say "we" you me "me".

<< Previous

Bullboard Posts

Next >>

dynaCERT leans into global growth with new HydraGEN orders